Nutrition and Protein-Energy Wasting on Hemodialysis

Bottom line

The albumin on the monthly lab sheet is the most over-read number in the dialysis unit. It predicts death well. It measures diet poorly.

• Wasting is common and lethal. Across 90 observational studies and 16,434 dialysis patients, the middle half of studies reported protein-energy wasting (PEW) in 28–54% of patients ¹. In a meta-analysis of 29 cohorts, malnutrition carried a hazard ratio for death of 1.53 in hemodialysis (Dr. Bland is a co-author of that meta-analysis) ².
• Albumin is partly an inflammation marker. Inflammation lowers albumin by speeding its breakdown; diet mainly affects its synthesis ^3,4. In a randomized trial, blocking IL-6 with clazakizumab raised albumin 0.21–0.28 g/dL in 12 weeks without changing what anyone ate ⁵.
• The targets are set. KDOQI 2020: protein 1.0–1.2 g/kg/day (1C), energy 25–35 kcal/kg/day (1C), sodium under 2.3 g/day (1C), and the 7-point Subjective Global Assessment as the assessment tool (1B) ⁶. Federal rules require albumin and weight at least monthly and a registered dietitian on the care team ⁷.
• Feeding improves numbers, not proven survival. In randomized trials, protein supplements raise albumin by about 0.2–0.3 g/dL ⁸. Intradialytic parenteral nutrition added to oral supplements did not lower two-year mortality in the only large randomized trial ⁹. The survival signal for in-center supplements comes from matched observational cohorts ^10,11.
• Eating on the machine is a trade. A small controlled study found 13 versus 2 episodes of symptomatic hypotension when patients ate during treatment ¹², yet an international consensus calls meals or supplements during treatment reasonable standard care for patients without contraindications ¹³. Feed the stable patient early. Do not feed the patient whose pressure is falling.
• Control phosphorus without cutting protein. Teaching patients to avoid phosphate additives lowered serum phosphorus in a cluster-randomized trial ¹⁴. A phosphorus target met by eating less protein is a wasting prescription.

1. What protein-energy wasting is

In 2008 the International Society of Renal Nutrition and Metabolism (ISRNM) replaced a tangle of overlapping terms — malnutrition, uremic malnutrition, cachexia, malnutrition-inflammation complex — with one: protein-energy wasting, the loss of body protein mass and fuel reserves ¹⁵. The word was chosen on purpose. “Malnutrition” implies that the fix is food. “Wasting” admits that inflammation, acidosis, hormonal disorders, and the dialysis procedure itself pull protein out of muscle even when the plate is full ^15,16.

The ISRNM diagnostic criteria

PEW requires findings in at least three of the four categories below, with at least one criterion in each, ideally documented on three occasions 2–4 weeks apart ¹⁵.

Source: Fouque 2008, Table 1 ¹⁵.

The definition is strict, which makes it specific and insensitive. KDOQI 2020 notes its low sensitivity and cites a mortality-prediction study in which the ISRNM criteria failed to predict death where the Subjective Global Assessment and the Malnutrition-Inflammation Score succeeded ⁶. Use the criteria to name the disease. Do not wait for them before acting.

How common, and how lethal

• Prevalence (meta-analysis of observational studies). Carrero and colleagues pooled 90 studies from 34 countries — 16,434 dialysis patients assessed by the Subjective Global Assessment or the Malnutrition-Inflammation Score. The 25th–75th percentile range of PEW prevalence was 28–54%, and geography was the only moderator that explained any of the heterogeneity ¹.
• Mortality (meta-analysis of cohorts). Across 29 cohorts and 11,063 dialysis patients, malnutrition was associated with death at HR 1.49 (95% CI 1.36–1.64) overall and 1.53 (1.38–1.70) in hemodialysis, versus 1.26 in peritoneal dialysis ².
• The original signal (observational). Lowrie and Lew’s 1990 analysis of more than 12,000 hemodialysis patients found a low albumin (below 4.0 g/dL) to be the laboratory value most strongly associated with death, and two-thirds of patients had one. A low creatinine, not a high one, also predicted death ¹⁷. In a dialysis patient, creatinine is a muscle-mass marker.

2. Why dialysis patients waste

The ISRNM etiology consensus lists the drivers: poor intake, increased energy expenditure, persistent inflammation, metabolic acidosis, endocrine disorders that together push muscle and fat toward catabolism, comorbid illness, physical inactivity and frailty, and the dialysis procedure itself ¹⁶. KDOQI 2020 adds anorexia, dietary restriction, and protein losses during dialysis ⁶.

The procedure is catabolic. A single high-flux session removed 8.0 ± 2.8 g of amino acids into the dialysate (6.1–7.2 g with other membranes) ¹⁸. Stable-isotope studies showed that hemodialysis increased whole-body proteolysis by 10% and muscle proteolysis by 133% ¹⁹. That is why the protein target on dialysis (1.0–1.2 g/kg/day) is higher than for a healthy adult, and why the low-protein diets used in advanced non-dialysis CKD — often 0.55–0.6 g/kg/day — must be reversed when dialysis starts ⁶.

The malnutrition-inflammation complex

Stenvinkel’s 1999 study of patients about to start dialysis tied malnutrition, inflammation (CRP), and carotid atherosclerosis together, a cluster often called the MIA syndrome ²⁰. Kalantar-Zadeh reframed it as the malnutrition-inflammation complex syndrome: low albumin, low cholesterol, low creatinine, low weight, and high CRP travel together and predict death together ^21,22. In a 12-month cohort that tested 10 markers head to head, CRP, the Malnutrition-Inflammation Score, and comorbidity were the only consistent independent predictors of death and hospitalization ²³.

The clinical point: a low albumin does not tell you whether the patient is starving, inflamed, or both. Usually it is both. Where the inflammation comes from, and which sources can be removed, is covered on Inflammation and fish oil (PISCES) in hemodialysis.

The obesity paradox

In the general population, a higher BMI shortens life. In hemodialysis the direction flips: overweight and obese patients live longer (observational) ^22,24. KDOQI 2020 accepts the association at grade 2B — overweight or obesity predicts lower mortality in maintenance hemodialysis, while underweight and morbid obesity predict higher mortality ⁶. The likely explanation is time horizon and competing risk: wasting kills in months, while the vascular damage of obesity takes years ²².

3. Assessment

Albumin: an inflammation marker as much as a nutrition marker

What albumin predicts. KDOQI 2020 grades serum albumin as a predictor of hospitalization and death at 1A, the strongest grade in the guideline ⁶.

What it does not measure well. Kaysen’s kinetic studies separated the mechanisms. Within the albumin range seen in dialysis, nutrition mainly affects albumin synthesis, while inflammation causes hypoalbuminemia by increasing its fractional catabolic rate ³. In a longitudinal cohort, each unit rise in log CRP lowered albumin by 0.124 g/dL per month, while each 0.1 g/kg/day rise in protein catabolic rate raised it by only 0.021 g/dL per month ⁴. Friedman and Fadem put it bluntly: people with simple starvation are rarely hypoalbuminemic, patients with congenital analbuminemia are not malnourished, and supplements have not clearly been shown to raise albumin ²⁵.

The cleanest demonstration came from a drug trial. In a randomized phase 2b trial, the anti-IL-6 antibody clazakizumab raised mean albumin by 0.28, 0.25, and 0.21 g/dL at 12 weeks across three doses, versus 0.04 g/dL with placebo, with no change in diet ⁵.

Method matters. The ISRNM threshold of 3.8 g/dL is defined by the bromcresol green method ¹⁵. Albumin assays differ; know which method your laboratory runs before comparing a result with a published cut-off.

nPCR: protein intake from urea kinetics

The normalized protein catabolic rate (nPCR, also called normalized protein nitrogen appearance, nPNA) estimates dietary protein intake from interdialytic urea generation ²⁸. In a stable patient, protein in equals protein broken down. KDOQI cautions that nPCR, like albumin and prealbumin, is influenced by non-nutritional factors ⁶; in a catabolic patient, urea generation reflects tissue breakdown as well as diet.

It still predicts outcomes. In a longitudinal cohort (observational), survival was best with nPNA 1.0–1.4 g/kg/day; values below 0.8 or above 1.4 were associated with higher mortality, and a falling nPNA over the first 6 months predicted death, although adjustment for the malnutrition-inflammation complex blunted the association substantially ²⁹. KDOQI 2020 treats nPCR, albumin, and prealbumin as complementary tools not to be interpreted in isolation (opinion) and lists nPCR as an alternative way to estimate intake (2D) ⁶.

Composite tools and body composition

• 7-point Subjective Global Assessment (SGA): history (weight change, intake, gastrointestinal symptoms, function) plus examination (fat and muscle loss, edema). KDOQI 2020 recommends it as valid and reliable in dialysis (1B) ^6,30.
• Malnutrition-Inflammation Score (MIS): SGA plus BMI, albumin, and transferrin (total iron-binding capacity), scored 0–30. It correlated with hospitalization and mortality in its derivation cohort ³¹. KDOQI 2020: may be used in hemodialysis (2C) ⁶.
• Handgrip strength: an indicator of protein-energy and functional status when earlier measurements are available for comparison (2B) ⁶. In a mixed hemodialysis and peritoneal dialysis cohort, low grip strength predicted mortality independent of modality ³². Serial values in the same patient are more useful than any single cut-off.
• Body composition: KDOQI 2020 suggests multi-frequency bioimpedance in hemodialysis patients when available, measured at least 30 minutes after the session ends (2C); DXA remains the reference standard when feasible (opinion). Weight and BMI alone cannot diagnose PEW unless BMI is below 18 ⁶.

Weight has to be read against the target weight. A patient who repeatedly finishes treatment below target is losing tissue, not water; if the target is not lowered, fluid will replace the lost flesh ^7,15. Target-weight assessment is covered on Estimating dry weight.

Who assesses, and how often

Federal Conditions for Coverage (42 CFR Part 494) ⁷:

• The interdisciplinary team must include a registered dietitian with at least 1 year of clinical nutrition experience (§494.80, §494.140(c)).
• The comprehensive assessment must include an evaluation of nutritional status by the dietitian (§494.80(a)(6)). The initial assessment is due within 30 days or 13 hemodialysis sessions, with reassessment within 3 months, then at least annually for stable patients and monthly for unstable patients. The listed examples of instability include extended or frequent hospitalization, marked deterioration, and concurrent poor nutritional status, unmanaged anemia, and inadequate dialysis (§494.80(b), (d)).
• The plan of care must address nutritional status, and albumin and body weight must be measured at least monthly (§494.90(a)(2)).
• Nutritional status is a required element of the facility’s quality program (§494.110).

KDOQI 2020 ⁶:

• Screen for PEW risk at least every 6 months (opinion); no single screening tool is preferred (2D).
• A registered dietitian nutritionist performs a comprehensive assessment within 90 days of starting dialysis, annually, or whenever screening or a provider triggers it (opinion).
• Medical nutrition therapy is provided by the dietitian in close collaboration with the physician or advanced practice provider (1C).
• A 3-day food record that covers dialysis and non-dialysis days is the preferred way to measure intake (2C).

A monthly surveillance table

4. Targets: KDOQI 2020

The 2020 update was a joint guideline of the National Kidney Foundation and the Academy of Nutrition and Dietetics, developed with scientific support from ISRNM ⁶. It is the governing nutrition guideline for US dialysis units. In the grades below, 1 is a recommendation and 2 a suggestion, the letter rates the certainty of evidence, and “opinion” marks an ungraded expert statement.

Source for the table: KDOQI 2020 ⁶, except where another reference is shown.

Protein versus phosphorus: do not trade one for the other

Protein and phosphorus travel together, and a phosphorus target met by cutting protein is a wasting prescription. This site’s review of phosphate management in ESRD makes the same argument from the other direction: a low phosphate in a dialysis patient often signals inadequate intake.

What lowers phosphorus without starving the patient:

• A lower phosphorus-to-protein ratio (observational). In a hemodialysis cohort, a dietary phosphorus-to-protein ratio of 16 mg/g or higher carried a death HR of 1.99 relative to 12–14 mg/g ³⁴. The goal is protein with less phosphorus attached.
• Avoiding additives (cluster-randomized trial). Inorganic phosphate from additives is more readily absorbed than organic phosphorus, and phytate-bound phosphorus in seeds and legumes is less bioavailable ³³. Teaching patients to avoid phosphate additives lowered serum phosphorus by 0.6 mg/dL more than control over 3 months (95% CI −1.0 to −0.1) ¹⁴. The teaching point: look for “PHOS” in the ingredient list.
• Plant protein (small crossover study). In 9 patients with a mean eGFR of 32, one week of a vegetarian diet lowered serum phosphorus and FGF23 compared with a meat diet of equivalent nutrients ³⁵. The study was small, short, and not in dialysis patients, but it is consistent with the lower bioavailability of phytate-bound phosphorus.

Fruit, vegetables, and potassium

Traditional renal diets strip out fruit and vegetables. In DIET-HD, a multinational cohort of 9,757 adults on hemodialysis (observational), patients ate a median of 8 servings of fruit and vegetables per week; only 4% met the general-population goal of 4 servings per day. The highest tertile of intake (median 17 servings per week) was associated with lower all-cause mortality than the lowest (HR 0.80; 95% CI 0.71–0.91) ³⁶. The comparison is confounded by health and appetite, but it removes the assumption that restriction is safe. Potassium management is covered on Dialysate potassium: bath selection and Hyperkalemia on HD.

Fluid

KDOQI’s volume lever is sodium: under 2.3 g/day (1C for volume control; 2B as an adjunct lifestyle measure) ⁶. Interdialytic weight gain, fluid allowances, and the sodium-thirst loop are covered on Estimating dry weight and Dialysate sodium.

5. Interventions

The escalation ladder

KDOQI 2020 and the ISRNM treatment consensus describe the same sequence: individualized counseling by the dietitian; oral nutritional supplements for at least 3 months; enteral tube feeding if oral intake remains inadequate; and parenteral nutrition — intradialytic parenteral nutrition (IDPN) in hemodialysis — when oral and enteral routes fail ^6,37. At each step, correct what can be corrected: underdialysis, acidosis, infection, depression, dentition, gastroparesis, and food access. The ISRNM consensus is candid: many epidemiologic studies link better nutritional markers to survival, but no large randomized trial has shown that a nutritional intervention lowers mortality or morbidity ³⁷.

flowchart TD
    A["Trigger<br>weight below target, repeatedly<br>albumin falling<br>nPCR under 0.8<br>poor appetite, SGA B or C"] --> B{"Inflamed or infected?<br>catheter, old graft, wounds,<br>teeth, recent admission"}
    B -- yes --> C["Treat the source<br>catheter to fistula,<br>resect infected graft,<br>dental referral"]
    B -- "no, or treated" --> D["Dietitian assessment<br>3-day food record,<br>SGA or MIS"]
    C --> D
    D --> E["Correct Kt/V and acidosis<br>(bicarbonate 24 to 26),<br>depression, GI symptoms,<br>food access"]
    E --> F["Oral supplement trial,<br>at least 3 months"]
    F --> G{"Improving at 3 months?"}
    G -- yes --> H["Continue; reassess monthly"]
    G -- no --> I["Consider enteral feeding<br>or an IDPN trial (2C)"]
    I --> J["Goals-of-care conversation<br>if wasting is refractory"]

Oral nutritional supplements

Randomized evidence, surrogate outcomes only.

• Cochrane 2020 (22 trials, 1,278 participants, 79% on hemodialysis, follow-up 1–12 months): protein-based supplements probably raise albumin — mean difference 0.19 g/dL overall (moderate certainty, I² 84%), 0.28 g/dL in hemodialysis, 0.31 g/dL in malnourished participants — and may raise prealbumin and mid-arm muscle circumference, with little effect on weight or BMI. No trial was powered for death ⁸.
• KDOQI’s own pooled analysis (11 studies): albumin +0.121 g/dL (95% CI 0.006–0.236), significant only for protein-energy formulas, with high heterogeneity ⁶.
• Liu 2018 (15 trials, 589 patients): too few comparable data to pool mortality ³⁸.

Observational evidence on survival, confounded.

• Lacson 2012 (a large dialysis organization; intradialytic supplements for albumin ≤3.5 g/dL; 5,227 matched pairs): intention-to-treat adjusted mortality HR 0.91 (0.85–0.98); as-treated HR 0.66 ¹⁰.
• Weiner 2014 (Dialysis Clinic, Inc.; 1,278 protocol patients against matched controls): mortality HR 0.71 (0.58–0.86) ¹¹.
• Cheu 2013 (a dialysis-provider health plan; 470 patients with albumin below 3.8 g/dL): supplements were associated with a 0.058 g/dL higher albumin and lower 1-year hospitalization; mortality was not significantly different ³⁹.

The gap between the intention-to-treat and as-treated estimates in the Lacson analysis (0.91 versus 0.66) is the healthy-adherer effect in plain view. Patients who can drink the supplement are healthier than patients who cannot.

Eating during hemodialysis

This is where nutrition and hemodynamics collide.

The case for. The procedure is catabolic ^18,19, and many patients arrive for an early chair time without having eaten. In a stable-isotope study, IDPN given during treatment converted whole-body and forearm-muscle protein balance from net negative to strongly positive, which shows that the intradialytic window is modifiable ⁴⁰. The 2018 ISRNM consensus concluded that meals or supplements during hemodialysis should be considered part of standard care for patients without contraindications. It also listed the challenges: postprandial hypotension and hemodynamic instability, aspiration risk, gastrointestinal symptoms, hygiene, staff burden, reduced solute removal, and cost ¹³.

The case against. In Sherman’s 1988 controlled study (9 nondiabetic patients, 125 treatments, a meal given in 62), blood pressure fell faster in the 45 minutes after eating, and symptomatic hypotension occurred 13 times in 5 fed patients versus twice in 1 fasting patient ¹². Blood pooling in the splanchnic circulation after a meal may also reduce delivered clearance; a 2020 review argued that these risks outweigh the nutritional benefit ⁴¹.

A newer pilot. Choi 2019 gave high-protein meals during 25 consecutive sessions. Symptomatic hypotension did not increase (18 events in 6 patients during the study versus 19 in 5 before), but nutritional status did not change either ⁴².

Intradialytic parenteral nutrition

• FineS (Cano 2007; RCT): 186 malnourished hemodialysis patients all received oral supplements and were randomized to add 1 year of IDPN or not. IDPN did not improve 2-year mortality (the primary endpoint), hospitalization, Karnofsky score, BMI, or laboratory markers. Both groups improved. A rise in prealbumin of more than 30 mg/L within 3 months predicted a 54% lower 2-year mortality: the response mattered, not the route ⁹.
• Marsen 2017 (open-label RCT): 83 patients in the full analysis set. IDPN raised prealbumin more often (41.0% versus 20.5% reached a rise of at least 15% by week 4), more so in moderate (SGA B) than in severe (SGA C) malnutrition. No hard outcomes were reported ⁴³.

KDOQI 2020 suggests an IDPN trial for PEW when oral and enteral intake cannot meet requirements (2C) ⁶. IDPN supplies partial nutrition on at most three sessions a week. It does not replace eating.

Appetite stimulants and anabolic agents

No appetite stimulant or anabolic agent has shown a patient-level benefit in hemodialysis. The ISRNM consensus lists them as potential adjuncts, not standard care ³⁷.

Exercise

• Cochrane (Heiwe 2011): 45 trials and 1,863 participants with CKD. Exercise improved aerobic capacity, walking capacity, blood pressure, and some nutritional parameters; half the trials were at high risk of bias ⁵¹.
• DiaTT (Anding-Rost 2023; cluster-randomized): 1,211 hemodialysis patients in Germany. Twelve months of combined endurance and resistance training during dialysis raised the 60-second sit-to-stand count by 3.85 repetitions over usual care (95% CI 2.22–5.48), improved timed up-and-go and 6-minute walk, and cut median hospital days per year from 5 to 2. Mortality was unchanged. Only 917 of the 1,211 were in the full analysis ⁵².
• PEDAL (Greenwood 2021; RCT): 379 UK patients and 6 months of intradialytic cycling. The quality-of-life primary outcome missed (difference 2.4; 95% CI −0.1 to 4.8), and adherence to the exercise prescription was 18% ⁵³.
• Resistance training increased quadriceps cross-sectional area and strength in the nandrolone factorial trial ⁴⁹.

Exercise preserves function. It has not been shown to reverse PEW or prolong life. The difference between DiaTT and PEDAL is dose and adherence: 12 months of combined training, measured against physical function, succeeded; 6 months of cycling with 18% adherence, measured against quality of life, did not ^52,53.

Evidence gaps

1. No nutritional intervention has a randomized mortality benefit in hemodialysis — not oral supplements, not IDPN, not appetite stimulants or anabolic agents ^8,9,37,50.
2. Eating during treatment needs a pragmatic trial that measures hypotension, delivered Kt/V, and nutrition together. The current evidence is a 9-patient study from 1988, small pilots, and consensus ^12,13,41,42.
3. Albumin as a quality metric rewards treating a number that inflammation controls ^7,25. How quality programs measure nutrition is taken up on Adequacy, nutrition, depression/cognition — and what quality metrics miss.
4. Exercise improves function, but no trial has shown that it reverses PEW or prolongs survival ^51,52,53.

At the chair

References

Numbered for this page. Every reference is drawn from the canonical evidence review for this module and was verified against its PubMed record or primary document (guideline, federal regulation, FDA label, trial registry, or company announcement) in September 2026.

1. Carrero JJ, Thomas F, Nagy K, et al. Global Prevalence of Protein-Energy Wasting in Kidney Disease: A Meta-analysis of Contemporary Observational Studies From the International Society of Renal Nutrition and Metabolism. J Ren Nutr. 2018;28(6):380-392. PMID: 30348259
2. Rashid I, Sahu G, Tiwari P, et al. Malnutrition as a potential predictor of mortality in chronic kidney disease patients on dialysis: A systematic review and meta-analysis. Clin Nutr. 2024;43(7):1760-1769. PMID: 38852509
3. Kaysen GA, Dubin JA, Müller HG, Mitch WE, Rosales LM, Levin NW. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int. 2002;61(6):2240-9. PMID: 12028466
4. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int. 2001;60(1):333-40. PMID: 11422769
5. Chertow GM, Chang AM, Felker GM, et al. IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat Med. 2024;30(8):2328-2336. PMID: 38796655
6. Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76(3 Suppl 1):S1-S107. PMID: 32829751
7. Centers for Medicare & Medicaid Services. Conditions for Coverage for End-Stage Renal Disease Facilities. 42 CFR Part 494 (§494.40, §494.80, §494.90, §494.110, §494.140), current as of September 2026. eCFR.
8. Mah JY, Choy SW, Roberts MA, et al. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020;5(5):CD012616. PMID: 32390133
9. Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol. 2007;18(9):2583-91. PMID: 17656473
10. Lacson E Jr, Wang W, Zebrowski B, Wingard R, Hakim RM. Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: a quality improvement report. Am J Kidney Dis. 2012;60(4):591-600. PMID: 22632807
11. Weiner DE, Tighiouart H, Ladik V, Meyer KB, Zager PG, Johnson DS. Oral intradialytic nutritional supplement use and mortality in hemodialysis patients. Am J Kidney Dis. 2014;63(2):276-85. PMID: 24094606
12. Sherman RA, Torres F, Cody RP. Postprandial blood pressure changes during hemodialysis. Am J Kidney Dis. 1988;12(1):37-9. PMID: 3389352
13. Kistler BM, Benner D, Burrowes JD, et al. Eating During Hemodialysis Treatment: A Consensus Statement From the International Society of Renal Nutrition and Metabolism. J Ren Nutr. 2018;28(1):4-12. PMID: 29249295
14. Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA. 2009;301(6):629-35. PMID: 19211470
15. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391-8. PMID: 18094682
16. Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr. 2013;23(2):77-90. PMID: 23428357
17. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15(5):458-82. PMID: 2333868
18. Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int. 1994;46(3):830-7. PMID: 7996804
19. Ikizler TA, Pupim LB, Brouillette JR, et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab. 2002;282(1):E107-16. PMID: 11739090
20. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899-911. PMID: 10231453
21. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42(5):864-81. PMID: 14582032
22. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793-808. PMID: 12631061
23. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant. 2004;19(6):1507-19. PMID: 15069177
24. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81(3):543-54. PMID: 15755821
25. Friedman AN, Fadem SZ. Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol. 2010;21(2):223-30. PMID: 20075063
26. Nassar GM, Fishbane S, Ayus JC. Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int Suppl. 2002(80):49-54. PMID: 11982813
27. Siribamrungwong M, Puangpanngam K. Treatment of periodontal diseases reduces chronic systemic inflammation in maintenance hemodialysis patients. Ren Fail. 2012;34(2):171-5. PMID: 22229644
28. Depner TA, Daugirdas JT. Equations for normalized protein catabolic rate based on two-point modeling of hemodialysis urea kinetics. J Am Soc Nephrol. 1996;7(5):780-5. PMID: 8738814
29. Shinaberger CS, Kilpatrick RD, Regidor DL, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis. 2006;48(1):37-49. PMID: 16797385
30. Steiber AL, Kalantar-Zadeh K, Secker D, McCarthy M, Sehgal A, McCann L. Subjective Global Assessment in chronic kidney disease: a review. J Ren Nutr. 2004;14(4):191-200. PMID: 15483778
31. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2001;38(6):1251-63. PMID: 11728958
32. Vogt BP, Borges MCC, Goés CR, Caramori JCT. Handgrip strength is an independent predictor of all-cause mortality in maintenance dialysis patients. Clin Nutr. 2016;35(6):1429-1433. PMID: 27083497
33. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(3):519-30. PMID: 20093346
34. Noori N, Kalantar-Zadeh K, Kovesdy CP, Bross R, Benner D, Kopple JD. Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(4):683-92. PMID: 20185606
35. Moe SM, Zidehsarai MP, Chambers MA, et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(2):257-64. PMID: 21183586
36. Saglimbene VM, Wong G, Ruospo M, et al. Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2019;14(2):250-260. PMID: 31738182
37. Ikizler TA, Cano NJ, Franch H, et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. 2013;84(6):1096-107. PMID: 23698226
38. Liu PJ, Ma F, Wang QY, He SL. The effects of oral nutritional supplements in patients with maintenance dialysis therapy: A systematic review and meta-analysis of randomized clinical trials. PLoS One. 2018;13(9):e0203706. PMID: 30212514
39. Cheu C, Pearson J, Dahlerus C, et al. Association between oral nutritional supplementation and clinical outcomes among patients with ESRD. Clin J Am Soc Nephrol. 2013;8(1):100-7. PMID: 23085729
40. Pupim LB, Flakoll PJ, Brouillette JR, Levenhagen DK, Hakim RM, Ikizler TA. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest. 2002;110(4):483-92. PMID: 12189242
41. Fotiadou E, Georgianos PI, Chourdakis M, Zebekakis PE, Liakopoulos V. Eating during the Hemodialysis Session: A Practice Improving Nutritional Status or a Risk Factor for Intradialytic Hypotension and Reduced Dialysis Adequacy? Nutrients. 2020;12(6). PMID: 32517256
42. Choi MS, Kistler B, Wiese GN, et al. Pilot Study of the Effects of High-Protein Meals During Hemodialysis on Intradialytic Hypotension in Patients Undergoing Maintenance Hemodialysis. J Ren Nutr. 2019;29(2):102-111. PMID: 30107974
43. Marsen TA, Beer J, Mann H. Intradialytic parenteral nutrition in maintenance hemodialysis patients suffering from protein-energy wasting. Results of a multicenter, open, prospective, randomized trial. Clin Nutr. 2017;36(1):107-117. PMID: 26708726
44. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J Ren Nutr. 2005;15(3):345-55. PMID: 16007564
45. Monfared A, Heidarzadeh A, Ghaffari M, Akbarpour M. Effect of megestrol acetate on serum albumin level in malnourished dialysis patients. J Ren Nutr. 2009;19(2):167-71. PMID: 19218044
46. Wazny LD, Nadurak S, Orsulak C, Giles-Smith L, Tangri N. The Efficacy and Safety of Megestrol Acetate in Protein-Energy Wasting due to Chronic Kidney Disease: A Systematic Review. J Ren Nutr. 2016;26(3):168-76. PMID: 26776251
47. Ashby DR, Ford HE, Wynne KJ, et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int. 2009;76(2):199-206. PMID: 19387475
48. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA. 1999;281(14):1275-81. PMID: 10208142
49. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol. 2006;17(8):2307-14. PMID: 16825332
50. Kopple JD, Cheung AK, Christiansen JS, et al. OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant. 2011;26(12):4095-103. PMID: 21750157
51. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev. 2011;2011(10):CD003236. PMID: 21975737
52. Anding-Rost K, von Gersdorff G, von Korn P, et al. Exercise during Hemodialysis in Patients with Chronic Kidney Failure. NEJM Evid. 2023;2(9):EVIDoa2300057. PMID: 38320198
53. Greenwood SA, Koufaki P, Macdonald JH, et al. Randomized Trial-PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis. Kidney Int Rep. 2021;6(8):2159-2170. PMID: 34386665

Also in the Maintenance Hemodialysis module

Part of the Maintenance Hemodialysis mastery module. Module index.

• M21: Inflammation and fish oil (PISCES) in hemodialysis
• M16: Adequacy, nutrition, depression/cognition — and what quality metrics miss
• M12: Cardiometabolic monitoring: lipids and statins, glycemic markers, cardiovascular screening
• M17a: Anemia: targets, ESAs, and hyporesponsiveness
• M17b: Anemia: iron, HIF-PH inhibitors, and transfusion
• M7: Intradialytic hypotension and dialysate cooling
• M5: Estimating dry weight: assessment, tools, probing
• M2: Hyperkalemia on HD: interdialytic control, binders, emergencies
• Clinical Mastery: Phosphate management in ESRD: quality metrics, outcomes, binders, and tenapanor